Ethosuximide (Zarontin)

Order Name: ETHOSUXIM Test Number: 4002550 Revision Date: 12/12/2022

TEST NAME		МЕТН	ODOLOGY		
Ethosuximide (Zarontin)		Immur	noassay (IA)	3616-0	
SPECIMEN REQUIREMENTS					
Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment	
Preferred	1 mL (0.5)	Serum	Clot Activator (Red Top, No-Gel)	Room Temperature	
Alternate 1	1 mL (0.5)	Plasma	EDTA (Lavender Top)	Room Temperature	
Instructions	Specimen Type: Red-top tube, lar barrier tubes is not recommended in drug level due to absorption may Specimen Storage: Room Tempe Specimen Collection: Transfer se prior to next dose. Peak or trough Special Instructions: State other	es: 0.6 mL (Note: This volume Does NOT allow for repeat testing). acimen Type: Red-top tube, lavender top (EDTA) tube OR green-top (heparin) tube. DO NOT USE A GEL-BARRIER TUBE. The use of gel- rier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease rug level due to absorption may be clinically significant. acimen Storage: Room Temperature acimen Collection: Transfer separated serum or plasma to a plastic transport tube. Oral: peak: two to four hours after dose; trough: immediately r to next dose. Peak or trough levels may be used to monitor therapy because blood levels are fairly constant. acimen Stability: Ambient: 14 days, Refrigerated : 14 days, Frozen: 14 days			
GENERAL INFORMATION					
Expected TAT	1 - 3 days	1 - 3 days			
Clinical Use		Ethosuximide is an anticonvulsant used to treat patients with petit mal, myoclonic, and akinetic seizures. Therapeutic drug monitoring is useful to optimize dose and avoid toxicity.			
Performing Labcorp Test Code	007443	007443			
Notes	Labcorp Test Code: 0074	Labcorp Test Code: 007443			

 Notes
 Labcorp Test Code: 007443

 CPT Code(s)
 80168

 Lab Section
 Reference Lab